<div id="readability-page-1"><p>Shum Financial Group Inc. purchased a new stake in  AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 5,336 shares of the company's stock, valued at approximately $1,235,000.</p><ul><li>3 Dividend Growth Stocks Analysts Are Upgrading for 2026</li></ul><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ABBV. Norges Bank acquired a new stake in shares of  AbbVie in the 2nd quarter worth $4,288,200,000.  Laurel Wealth Advisors LLC grew its holdings in shares of  AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period.  Assenagon Asset Management S.A. increased its position in  AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company's stock worth $804,116,000 after purchasing an additional 3,666,521 shares during the last quarter.  Vanguard Group Inc. increased its position in  AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the last quarter.  Finally, Kingstone Capital Partners Texas LLC purchased a new position in  AbbVie during the second quarter worth about $581,817,000. Institutional investors and hedge funds own  70.23% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have recently weighed in on the stock. Morgan Stanley raised their price target on shares of AbbVie from $261.00 to $269.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, December 12th. UBS Group raised their target price on AbbVie from $195.00 to $220.00 and gave the stock a &#34;neutral&#34; rating in a research note on Friday, November 7th. BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, September 12th. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, October 20th. Finally, Wall Street Zen upgraded shares of AbbVie from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, December 13th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued  a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $245.84.</p><ul><li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li></ul><p><b>Check Out Our Latest Research Report on AbbVie</b></p><h2>AbbVie Stock Performance</h2><p>Shares of AbbVie stock opened at $228.55 on Thursday. The stock has a market capitalization of $403.94 billion, a price-to-earnings ratio of 173.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.36. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The business has a 50-day moving average of $226.67 and a 200 day moving average of $213.37. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. </p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the firm earned $3.00 earnings per share. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.  As a group, sell-side analysts forecast that  AbbVie Inc. will post 12.31 earnings per share for the current year. </p><h2>AbbVie Increases Dividend</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.0%. This is a boost from AbbVie's previous quarterly dividend of $1.64. AbbVie's dividend payout ratio  is 496.97%. </p><h2>About AbbVie</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than AbbVie</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Shum Financial Group Inc. acquired a new stake in AbbVie Inc. (NYSE:ABBV) worth approximately $1.24 million in the 3rd quarter, purchasing 5,336 shares. Other institutional investors have also increased their stakes in AbbVie, with significant investments from Norges Bank and Laurel Wealth Advisors. Analysts have raised price targets for AbbVie, with a consensus rating of "Moderate Buy" and a target price of $245.84. AbbVie recently reported strong quarterly earnings and announced a dividend increase to $1.73 per share, reflecting a 3.0% yield.</p>

Shum Financial Group Inc. Takes $1.24 Million Position in AbbVie Inc. $ABBV